Talk Bio

Vertex's povetacicept met its Phase 3 primary endpoint in IgA nephropathy (IgAN) with a 50-52% reduction in proteinuria versus placebo after 36 weeks 1 2 . The drug showed positive secondary endpoints, including reduction in abnormal antibodies and hematuria resolution, with mostly mild side effects like respiratory infections 1 . Vertex plans to complete its accelerated FDA approval application by end of March 2026 using a priority review voucher for a 6-month review 1 2 . Analysts see multibillion-dollar potential, with povetacicept outperforming Otsuka's Voyxact on proteinuria, but eGFR data at 2 years will be key for long-term efficacy and competition 1 2 . Vertex stock rose nearly 9% post-announcement on March 9, 2026, reflecting market enthusiasm for this kidney drug beyond its CF franchise 1 2 . While promising, full differentiation from competitors like Vera Therapeutics awaits confirmatory eGFR results later in 2026 1 . Sources: 1. https://www.biopharmadi...